Lisa Marx

Lisa Marx

Auto-generated profile, based on publicly available information

Lisa Marx

University of Freiburg 5 Department of General and Visceral Surgery, Faculty of Medicine Freiburg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CBChristopher Berlin
Christopher Berlin
FCFélicie Cottard
Félicie Cottard
DWDominica Willmann
Dominica Willmann
SUSylvia Urban
Sylvia Urban
STStephan M. Tirier
Stephan M. Tirier
RSRoland Schüle
Roland Schüle
Colorectal cancer is among the leading causes of cancer-associated deaths worldwide. Treatment failure and tumor recurrence due to survival of therapy-resistant cancer stem/initiating cells represent major clinical issues to overcome. In this study, we identified lysine methyltransferase 9 (KMT9), an obligate heterodimer composed of KMT9α and KMT9β that monomethylates histone H4 at lysine 12 (H4K12me1), as an important regulator in colorectal tumorigenesis. KMT9α and KMT9β were overexpressed in colorectal cancer and colocalized with H4K12me1 at promoters of target genes involved in the regulation of proliferation. Ablation of KMT9α drastically reduced colorectal tumorigenesis in mice and prevented the growth of murine as well as human patient-derived tumor organoids. Moreover, loss of KMT9α impaired the maintenance and function of colorectal cancer stem/initiating cells and induced apoptosis specifically in this cellular compartment. Together, these data suggest that KMT9 is an important regulator of colorectal carcinogenesis, identifying KMT9 as a promising therapeutic target for the treatment of colorectal cancer. Significance: The H4K12 methyltransferase KMT9 regulates tumor cell proliferation and stemness in colorectal cancer, indicating that targeting KMT9 could be a useful approach for preventing and treating this disease.

25 June 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
CLClaudia Lässle
Claudia Lässle
BMBernhard Mauerer
Bernhard Mauerer
LMLisa Marx
Lisa Marx
RFReinhild Feuerstein
Reinhild Feuerstein
HBHeidi Braumüller
Heidi Braumüller
RKRebecca Kesselring
Rebecca Kesselring
Obesity is a global epidemic characterized by energy disequilibrium, metabolic disorders, and fat mass development that greatly affect the health status of individuals. There is evidence that the intake of a high-fat diet and overweight are associated with the incidence of colorectal cancer (CRC). Metabolic surgery has been associated with improvements in obesity-related comorbidities and a reduction in the overall cancer risk. However, the underlying mechanism by which metabolic surgery reduces the risk of CRC remains unknown. To understand the antitumoral mechanism of bariatric surgery, we analyzed the development of CRC after Roux-en-Y gastric bypass (RYGB) surgery in an RYGB-CRC mouse model. Here, we showed that RYGB surgery substantially reduced primary tumorigenesis and prevented metastasis. This protective effect was mediated by bile acid (BA) exclusion from the proximal small intestine, leading to BA diversion in the preceding parts of the gastrointestinal tract and in circulation. The diverted BA profile in RYGB mice showed antitumoral and antimetastatic effects that were verified by BA exclusion of the proximal small bowel without the systemic metabolic installations of RYGB surgery by a cholecystointestinal shunt (CIS) surgery. RYGB surgery thus leads to reduced primary BAs and elevated secondary BAs in circulation. In a translational study involving patients with CRC with metachronous liver metastases, we confirmed that reduced primary BA concentrations in the serum were associated with prolonged time to metastasis, underscoring the critical role of BAs in CRC progression and metastatic development.

1 February 2026 in Cancer Research Communications
Verified
Journal Article
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Combining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer. Nevertheless, responses of these poor prognostic cancers are short-lived and heterogeneous, thereby highlighting the unmet need for novel concepts integrating targeted therapy and immuno-oncology. To this end, an immunocompetent mouse model with reliable disease onset and responding to clinically relevant drugs is essential but unavailable. In this study, we generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations and characterized their ground state and responses to targeted therapy compounds in detail by RNA sequencing, whole-exome sequencing, and various functional assays. Interestingly, these so-called NaJa lines displayed distinct differentiation states and responses to the clinically relevant RAF inhibitors (RAFi) encorafenib and exarafenib, thereby resembling the clinical heterogeneity of BRAFV600E-driven colorectal cancer. RAFi resistance was overcome by the EGFR family inhibitor afatinib. RAFis also influenced the expression of the antigen presentation machinery, cytokines, and other immunomodulatory factors. Upon retransplantation into syngeneic mice, all NaJa lines established aggressive tumors with distinct tumor microenvironments matching their differentiation states. Thus, the NaJa lines provide a unique tool to study tumor heterogeneity, drug resistance, and the interplay between tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer. Significance: We present three newly isolated syngeneic BRAFV600E-driven colorectal cancer cell lines with distinct in vitro and in vivo phenotypes. They differ in their response to drug treatments, resemble patient tumor heterogeneity, and enable efficient tumor growth in immunocompetent mice for tumor-immune microenvironment studies.

31 March 2023
Verified
Other
Open access
CBChristopher Berlin
Christopher Berlin
FCFélicie Cottard
Félicie Cottard
DWDominica Willmann
Dominica Willmann
SUSylvia Urban
Sylvia Urban
STStephan M. Tirier
Stephan M. Tirier
RSRoland Schüle
Roland Schüle
File with all the Supplementary Tables (Supplementary Tables S1-S3)

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Supplementary Figure S16 shows a focus assay, Western blot and kinase assay characterizing the MC38-associated BRAF W450C mutation.

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Supplementary Figure S15 shows membranes from the cytokine array and cell line–specific cytokine heatmaps of NaJa cells.